Computational pathology-informed immune biomarker for trastuzumab benefit in HER2+ breast cancer: Validation in NSABP B-41 clinical trial. Analysis of event-free survival (EFS) of stromal tumor ...
A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved their quality of life. By Gina Kolata Breast cancer patients whose tumors have ...
A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to cancer cells and not normal cells, potentially allowing clinicians to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback